2019 Analysis of the Global Melanoma Treatment Market - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Melanoma Treatment Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

The Melanoma Treatment market is expected to reach $9.70 billion by 2026 growing at a CAGR of 14.6% during 2018 to 2026.

Melanoma is a type of skin cancer that develops in the melanocyte cells that are responsible for producing melanin, the pigment responsible for imparting colour to the skin. It occurs when unrepaired damage to skin cells leads to their rapid multiplication, thus forming malignant tumours. The primary cause of Melanoma is prolonged exposure to ultraviolet light. If detected and treated at an early stage, the disease is almost always curable. Its treatment includes radiation therapy, biological therapy and many other options.

Factors such as the increase in the number of melanoma cases reported, growing health awareness among people, and environmental changes are driving the market growth. Though, side effects related to the treatment procedures restrain the market growth. Moreover, increase in the number of Food and Drug Administration's fast track approval and extensive adoption of novel therapeutics are the opportunities for the melanoma treatment market.

Based on therapy, the targeted therapy segment is going to have a lucrative growth during the forecast period, due to its high efficacy coupled with minimum side effects.

The key vendors mentioned are Merck & Co Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb, Amgen Inc, Iovance Biotherapeutics Inc, Pfizer Inc, Eisai Co Ltd, GlaxoSmithKline, AVAX Technologies, AstraZeneca, Biogen Idec, Medarex, Reliance Life Sciences, Sanofi, and Roche.

Key Questions Answered in this Report:

• How this market evolved since the year 2016
• Market size estimations, forecasts and CAGR for all the segments presented in the scope
• Key Market Developments and financials of the key players
• Opportunity Analysis for the new entrants
• SWOT Analysis of the key players
• Fastest growing markets analysed during the forecast period
  

Key Topics Covered:

1 Market Synopsis

2 Research Outline

2.1 Research Snapshot

2.2 Research Methodology

2.3 Research Sources

2.3.1 Primary Research Sources

2.3.2 Secondary Research Sources

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Melanoma Treatment Market, By Type

5.1 Introduction

5.2 Mucosal Melanoma

5.3 Ocular Melanoma

5.4 Lentigo Maglina Melanoma

5.5 Acral Lentigious

5.6 Nodular Melanoma

5.7 Superficial Melanoma

5.8 Cutaneous Melanoma

6 Global Melanoma Treatment Market, By Therapy

6.1 Introduction

6.2 Chemotherapy

6.3 Radiation Therapy

6.4 Targeted Therapy

6.5 Surgical Treatment

6.6 Immunotherapy

6.7 Pharmacological Treatment

6.8 Biologic Therapy

7 Global Melanoma Treatment Market, By Drug

7.1 Introduction

7.2 Keytruda

7.3 Opdivo

7.4 Yervoy

7.5 Mekinist+Tafinlar

7.6 Cotellic

7.7 Imlygic

7.8 Generics

7.9 Zelboraf

8 Global Melanoma Treatment Market, By Stage

8.1 Introduction

8.2 Stage 0

8.3 Stage I

8.4 Stage II

8.5 Stage III

8.6 Stage IV

9 Global Melanoma Treatment Market, By Application

9.1 Introduction

9.2 Hospitals and Clinics

9.3 Research Centres

9.4 Pharmaceutical Companies

9.5 Laboratories

10 Global Melanoma Treatment Market, By Geography

10.1 North America

10.2 Europe

10.3 Asia Pacific

10.4 South America

10.5 Middle East & Africa

11 Strategic Benchmarking

12 Vendors Landscape

12.1 Merck & Co. Inc

12.2 F. Hoffmann-La Roche Ltd

12.3 Novartis AG

12.4 Bristol-Myers Squibb

12.5 Amgen Inc

12.6 Iovance Biotherapeutics Inc

12.7 Pfizer Inc.

12.8 Eisai Co Ltd

12.9 GlaxoSmithKline

12.10 AVAX Technologies

12.11 AstraZeneca

12.12 Biogen Idec

12.13 Medarex

12.14 Reliance Life Sciences

12.15 Sanofi

12.16 Roche

For more information about this report visit https://www.researchandmarkets.com/r/u4jhma